On December 11, 2025 the European Parliament and the Council reached a provisional deal on the EU pharmaceutical package, and the part that matters most to generic and biosimilar planning is the new arithmetic of regulatory protection. As of October 2026 the deal is text awaiting final adoption, not law in force, so everything below describes what has been agreed and not yet what applies.
What the current rules give
Article 10(1) of Directive 2001/83/EC is the baseline. A generic applicant may rely on the reference product's data once it has been authorised "for not less than eight years", and the generic cannot be placed on the market until ten years have passed from the initial authorisation. The ten years can be extended to a maximum of eleven where, within the first eight, the holder obtains authorisation for a new indication with significant clinical benefit. That is the familiar 8+2+1 shape. The text of Article 10 of the Directive is the place to read the conditions.
What the deal says
According to the Parliament's press release on the deal, the new model has 8 years of regulatory data protection, during which other companies cannot access the product data, followed by 1 year of market protection, during which generics and biosimilars cannot be sold. Three conditions each add a further 12 months of market protection: the product addresses an unmet medical need; the product contains a new active substance and meets a combination of conditions (comparative clinical trials, trials in several member states, and an EU marketing authorisation application within 90 days of the first application outside the Union); or the holder obtains one or more new indications bringing significant clinical benefit. The combined regulatory protection period is capped at 11 years.
The same release gives breakthrough orphan medicinal products up to 11 years of market exclusivity, and a transferable 12-month data exclusivity voucher for priority antimicrobials.
| Current (Directive 2001/83/EC, Art. 10(1)) | Agreed in the package | |
|---|---|---|
| Data protection | 8 years | 8 years |
| Baseline market protection | 2 years (generic marketing from year 10) | 1 year (from year 9) |
| Add-ons | 1 year for a new indication with significant clinical benefit | 12 months each for unmet need, for a new active substance meeting the trial and filing conditions, for a new indication |
| Ceiling | 11 years | 11 years |
Source: the European Parliament press release of December 11, 2025, and Directive 2001/83/EC, Article 10, both linked above.
What this changes in practice
The ceiling did not move. The baseline did: a product with no add-on now reaches the market-protection end at year 9 where it used to reach it at year 10, and holders have to qualify for each extra year rather than receive two of the three years automatically. Reaching the 11-year ceiling now takes two of the three add-ons (8 + 1 + 1 + 1), where it used to take one qualifying indication, and a third add-on would add nothing under the cap.
For generic and biosimilar developers the useful reading is the other way round: a product that meets none of the conditions has one year less of market protection than before, and the qualification questions (unmet need, comparative trials, timing of the EU filing) become facts to establish in the dossier. The press release does not say how the conditions will be assessed, who decides, or at what point in the life of the product. That detail is in the legal text, which this note does not reproduce.
What is still open
The Parliament's legislative tracker records Coreper's endorsement of the compromise on March 6, 2026 and the health committee's approval on March 18, 2026, with Council adoption expected after the summer and a plenary vote indicatively in October 2026. It gives no entry-into-force date and no transition period, and neither does the press release. Dates for application, and the treatment of products already authorised or in development, are therefore not available from these sources.
For a reader watching several markets, the practical point is that the headline "11 years" is unchanged, so a comparison with the Russian rules on data and marketing exclusivity or the change in the United Arab Emirates should be made on the baseline and on what must be proved for each extra year.